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AbstrACt
Objectives This study was conducted to determine the 
prevalence of and associated risk factors for infection with 
oral high-risk human papillomavirus (HR-HPV) in adult 
participants within England, and to explore any association 
with oral mucosal buccal epithelial cell and whole blood 
folate concentration.
Design This was an observational study to determine oral 
HR-HPV prevalence in the study population. A case–control 
study was performed to explore the association between 
infection and folate status.
setting This study was conducted in Shefield, UK, 
between April 2013 and August 2014.
Participants Seven hundred participants, aged 18–
60 years, were recruited from university students (n=179), 
university and hospital staff (n=163), dental hospital 
patients (n=13), Sexual Health Shefield patients (n=122) 
and the general public (n=223).
Interventions Participants completed a lifestyle and 
sexual behaviour questionnaire, provided an oral rinse and 
gargle sample for the detection of oral HR-HPV and an oral 
mucosal buccal epithelial cell sample for the measurement 
of oral mucosal buccal epithelial cell folate. A blood sample 
was collected for measurement of whole blood folate 
concentration.
Outcome measures The prevalence of oral HR-HPV 
infection in the study population was the primary outcome 
measure. Secondary outcome measures included 
associations between risk factors, folate status and infection.
results The prevalence of oral HR-HPV infection in this 
cohort was 2.2% (15/680) with 0.7% (5/680) positive for 
HPV16 or HPV18. Twenty samples were excluded due to 
insuficient material for HPV detection. Participants with 
oral HR-HPV infection were more likely to be a former 
smoker, and have a greater number of sexual and oral 
sexual partners. Folate status was not linked to likelihood 
of HPV infection.
Conclusions The prevalence of oral infection with HR-
HPV in adult men and women in Shefield in the North of 
England was low. Smoking and sexual behaviour were 
associated with HR-HPV positivity.
trial registration number ID14106.
IntrODuCtIOn 
Rates of oropharyngeal cancer (OPC) are 
increasing worldwide, attributable to an 
increase in the incidence of oral infection with 
high-risk human papillomavirus (HR-HPV).1 
There are large geographical variations in the 
proportion of OPC cases associated with HPV 
infection; a recent study found that 59.3% of 
North American, 31.1% of European and just 
4.1% of South American OPC samples were 
positive for HPV16.2 Given the increase in 
HPV positive OPC, there is current interest 
in generating reliable data for prevalence of 
oral HPV infection and monitoring trends, so 
as to better understand aetiology of infection 
and progression to cancer. Greater knowl-
edge of the prevalence of oral HPV infec-
tion is particularly timely given the ongoing 
debate regarding HPV vaccination in males.3 
A recent meta-analysis of 29 studies world-
wide, with over 22 000 participants, found an 
overall prevalence of 2.7% oral HR-HPV infec-
tion.4 The majority of studies reporting oral 
HR-HPV prevalence have been performed 
in North or South America and there is a 
lack of published data available about the 
prevalence of oral HR-HPV in the UK. The 
Scottish HOPSCOTCH trial collected oral 
rinse and gargle samples from 380 partic-
ipants and reported a prevalence of 3.7% 
oral HR-HPV infection in males and females 
aged 16–69, recruited through dental prac-
tices.5 The only study previously performed 
in London, England reported 5.9% HR-HPV 
prevalence in HIV-negative men who have sex 
strengths and limitations of this study
 Ź This is the irst report on the prevalence of oral high-
risk human papillomavirus (HR-HPV) infection in 
men and women in England.
 Ź The low prevalence of infection may confer only lim-
ited ability to conidently determine risk factors for 
oral HR-HPV infection and associations with folate 
status.
 Ź Self-reported sexual, smoking and alcohol be-
haviours were collected using non-validated ques-
tionnaires and as such may not be accurate.
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with men (MSM).6 The lack of information about oral 
HR-HPV prevalence for the English population consti-
tutes an important knowledge gap.
Sexual behaviour and smoking status are considered to 
be the most important predictors of infection with oral 
HR-HPV.4 7 8 Additionally, there is evidence that the vitamin 
folate may influence the risk of HPV-linked cancers through 
mechanisms relating to HPV infection and persistence.9 
Studies by our group and others have shown that low red 
cell folate status is associated with an increased risk of 
cervical HPV infection,10 11 HPV persistence9 and cervical 
intraepithelial neoplasia or invasive cervical cancer.11 The 
association between oral HR-HPV infection and folate status 
has not previously been studied. Here, we have investigated 
the prevalence of oral HR-HPV infection in participants in 
Sheffield, England, and explored associated risk factors and 
folate status.
MethODs
study design
A case–control study design was used to compare folate 
status of HR-HPV positive participants matched to 
three HR-HPV negative control samples; matched for 
gender, age and smoking status. The sample size for the 
case–control study was based on our data from a nested 
case–control study of cervical cell folate concentration 
in women with HR-HPV infection that persists (cases) 
and those in whom the virus is cleared (controls) over 
6 months.12 We detected an almost two fold difference 
in mean folate concentration in cervical cells from cases 
versus controls (mean±SD, 5.4 ±4.83 ng folate/mg protein 
in cases vs 2.8 ±2.70 controls). We calculated that 50 cases 
with 150 controls would allow us to detect a 45% differ-
ence between cases (oral HR-HPV positive) and controls 
(oral HR-HPV negative) in oral mucosal buccal epithelial 
cell folate, with a power of 80% and p<0.05.
Reported prevalence values for oral HPV are extremely 
variable and there were few data from the UK at the time 
of the study. Jalal et al13 reported a 44% prevalence of 
HR-HPV in oral epithelial cells in a UK sample. Gillison 
et al
8 reported an age-dependent prevalence of between 
4.2% and 11.4% oral HPV infection and an average of 
3.7% with HR-HPV. A sample size of 700 was selected, 
assuming a prevalence of 7% in the population sampled.
recruitment
Seven hundred men and women between 18 and 60 years 
were recruited between April 2013 and August 2014 in 
Sheffield, UK. Sheffield is a city with a population of 
570 000, of which approximately 50 000 are students 
attending two universities. Sheffield has lower salaries 
for those in full-time employment compared with the 
national average; however, this is seen across many cities 
in the North of England. While no socioeconomic data 
were collected as part of this study, it is expected the 
results are applicable to other Northern English cities.
Participants were recruited from across Sheffield 
including: university students (179), university and 
hospital staff (163), dental hospital patients (13), Sexual 
Health Sheffield patients (122) and the general public 
(223). Recruitment was achieved through university and 
hospital email distribution lists, posters, patient letters, 
newspaper adverts and on-site recruitment at hospital 
locations to obtain a diverse study population.
 Exclusion criteria included previous HPV vaccination, 
oral lesions (any lesion which would cause pain or discom-
fort during oral mucosal buccal epithelial cell collection), 
previous diagnosis of oral cancer and/or inability to 
understand or comply with study procedures.
sampling and questionnaire
Participants were asked to complete a questionnaire 
relating to smoking status, alcohol consumption and 
sexual history adapted from a previous trial.14 A full copy 
of the questionnaire can be found in online supplemen-
tary figure 1. Example questions include:
‘How many different sexual partners have you had in 
your lifetime?’ and ‘Have you ever performed oral sex on a 
partner?’
Each participant provided a finger-prick blood sample 
for the analysis of whole blood folate.
Oral mucosal buccal epithelial cell samples were collected 
by brushing the buccal mucosa (the cheek mucosa within 
the oral cavity) with an Orcellex soft brush (Rovers Medical 
Devices, The Netherlands) using 10 rotations of the brush 
on the mucosal buccal surface to collect the cells. Cells were 
dislodged into phosphate buffered saline and centrifuged 
at 250xg for 10 min. Cell pellets were then weighed, resus-
pended in 500 µL of 1.0% ascorbate and incubated for 90 min 
at room temperature. Following incubation samples were 
snap frozen in liquid nitrogen to aid cell lysis and stored at 
−80°C. Collected frozen oral mucosal buccal epithelial cells 
and blood samples were transported to the Rowett Institute 
of Nutrition and Health, Aberdeen, UK, for the measure-
ment of folate using the SimulTRAC-S radioassay kit, (MP 
Diagnostics, supplied by Anachem, Bedford, UK).
Oral exfoliated cells from the oropharynx and oral cavity 
were collected for HPV detection by 30 s rinse and gargle 
with saline. HPV detection was carried out in the Cytology 
Department of the Royal Hallamshire Hospital, Sheffield 
Teaching Hospitals National Health Service (NHS) Foun-
dation Trust, using the Linear Array HPV genotyping assay 
on a Roche platform, presence of β-globulin was used as a 
biomarker of sample validity. Samples were tested for the 
presence of HR-HPV subtypes 16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 66, defined as group 1 human carcinogens 
according to the International Agency for Research on 
Cancer along with subtype 68, a class 2a carcinogen.15
statistical analysis
All statistical analyses were performed using SPSS V.21. 
Logistic regression analysis was conducted to determine the 
influence of age, gender, smoking, alcohol consumption and 
sexual behaviour, on risk of being HR-HPV positive, using 
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data from the whole dataset. Additionally, every person who 
tested HR-HPV positive was matched with three individuals 
who tested HR-HPV negative, matching for age, gender and 
smoking status. Logistic regression analysis was used to deter-
mine the influence of whole blood folate and buccal cell 
folate on likelihood of being HR-HPV positive, using data 
from the whole dataset and, separately, data from matched 
samples.
Patient and public involvement
No participants were involved with the study design.
results
The characteristics of participants recruited to the study 
are shown in table 1, for all participants and according to 
HR-HPV status.
Table 1 Characteristics of study participants
All (n=700)*
HR-HPV positive 
(n=15)*
HR-HPV negative 
(n=665)*
OR for HR-HPV positivity 
(95% CI)
Age (year), n (%)
  18–25 223 (31.9) 2 (13.3) 213 (32.0) 0.71 (0.06 to 7.98)
  26–30 106 (15.1) 4 (26.7) 101 (15.1) 3.10 (0.33 to 27.48)
  31–40 168 (24.0) 5 (33.3) 156 (23.5) 2.43 (0.28 to 21.22)
  41–50 123 (17.6) 3 (20.0) 119 (17.9) 1.92 (0.20 to 18.75)
  51–60 80 (11.4) 1 (6.7) 76 (11.4) 1.0
Sex, n (%)
  Male 424 (60.6) 13 (86.7) 397 (59.7) 4.39 (0.98 to 19.60)
  Female 276 (39.4) 2 (13.3) 268 (40.3) 1.0
Smoking status, n (%)
  Never smoked 407 (58.1) 6 (40.0) 389 (58.5) 1.0
  Former smoker 180 (25.7) 8 (53.3) 166 (25.0) 3.12 (1.07 to 9.15)
  Current smoker 113 (16.1) 1 (6.7) 110 (16.5) 0.59 (0.07 to 4.95)
Units of alcohol per week, n (%)
  <1 153 (21.9) 4 (26.7) 145 (21.8) 1.0
  1–10 241 (34.4) 4 (26.7) 233 (35.0) 0.62 (0.15 to 2.53)
  >10≤20 172 (24.6) 1 (6.7) 168 (25.3) 0.22 (0.02 to 1.95)
  20+ 134 (19.1) 6 (40.0) 119 (17.9) 1.83 (0.50 to 6.63)
  Mean (SD) 11.8 (12.9) 16.7 (19.2) 11.5 (12.7)
No of sexual partners, n (%)
  0–5 332 (47.4) 2 (13.3) 330 (49.6) 1.0
  6–10 173 (24.7) 6 (40.0) 167 (25.1) 5.93 (1.18 to 29.69)
  11+ 157 (22.4) 7 (46.7) 150 (22.6) 7.70 (1.58 to 37.51)
  No answer 38 (5.4) 0 (0) 18 (2.7)
  Mean (SD) 11.4 (38.3) 14.4 (12.2) 11.5 (39.3)
No of oral sexual partners, n (%)
  0–5 496 (70.9) 5 (33.3) 474 (71.3) 1.0
  6–10 109 (15.6) 8 (53.3) 104 (15.6) 7.29 (2.34 to 22.74)
  11+ 85 (12.1) 2 (13.3) 77 (11.6) 2.46 (0.47 to 12.92)
  No answer 10 (1.4) 0 (0) 10 (1.5)
  Mean (SD) 6.6 (13.6) 8.2 (7.0) 6.6 (13.9)
Age at sexual debut (year)
  Mean 17.73 (3.14) 17.66 (3.15) 17.78 (3.52) 1.01 (0.86 to 1.20)
  Logistic regression p=0.892
*Twenty oral rinse and gargle samples contained insuficient cellular material (measured through β-globulin) to determine HPV status and were 
therefore omitted.
HR- HPV, high-risk human papillomavirus. OR, odds ration. SD, standard deviation. 
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Fifteen people (2.2%) tested positive for an oral 
HR-HPV infection. Of these 4 were positive for HPV16, 1 
for HPV18 and the remaining 10 participants tested posi-
tive for HR-HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59, 66 and 68 (specific type not distinguishable with this 
detection method).
Former smokers were significantly more likely to be 
HR-HPV positive compared with those who had never 
smoked (OR 3.12, 95% CI 1.07 to 9.15), while the sample 
size for current smokers was insufficient to judge risk for 
this population. Participants who had a greater number 
of sexual partners (more than six) were significantly 
more likely to be HR-HPV positive compared with those 
with fewer than six sexual partners (6–10 partners OR 
5.93, 95% CI 1.18 to 29.26, 11+ partners (OR 7.70, 95% CI 
1.58 to 37.51). Participants with 6–10 oral sexual part-
ners were also at increased risk of HR-HPV compared 
with those reporting fewer oral sexual partners (OR 7.29, 
95% CI 2.34 to 22.74). Participants reporting more than 
11 oral sexual partners had an increased prevalence of 
HR-HPV  (OR 2.46,  95%  CI  0.47  to   12.92) , however, 
this did not reach statistical significance.
Whole blood folate in participants who tested 
HR-HPV positive was (mean±SD), 175.4±47.8 ng/mL, 
164.3±64.3 ng/mL in those who tested HR-HPV negative 
and 156.4±43.7 ng/mL in matched HR-HPV negative 
controls (figure 1).
Oral mucosal buccal epithelial cell folate concen-
tration was 0.0524±0.0566 ng/mg cell pellet in partici-
pants who tested HR-HPV positive, 0.0514±0.0631 ng/
mg cell pellet in participants who tested HR-HPV nega-
tive and 0.0544±0.0644 ng/mg cell pellet in in matched 
HR-HPV negative controls (matched to HR-HPV positive 
by gender, age and smoking status (figure 1)). Neither 
whole blood folate nor oral mucosal buccal epithelial 
cell folate was significantly associated with risk of oral 
HR-HPV infection.
DIsCussIOn
The prevalence of oral HR-HPV infection observed in 
this study (2.2%) was in line with the global review and 
meta-analysis performed by Shigeishi and Sugiyama 
which reported 2.7% oral HR-HPV infection.4 However, 
the prevalence in this study was lower than two previous 
studies performed in the UK that reported a preva-
lence of 3.7% in a Scottish cohort of 380 participants 
attending dental clinics5 and a prevalence of 5.9% in 
MSM in London.6 This variation in prevalence was not 
surprising given the differences in study populations. 
Our cohort had a higher proportion of participants 
under the age of 25 compared with the participants in 
Scotland and it has previously been shown that there 
is a weak association between increasing age and oral 
HR-HPV prevalence.8 The London study population 
was made up of MSM and the prevalence reported 
(5.9%) was comparable to previous reports of oral 
HR-HPV infection in MSM (6.0%).4 These prevalence 
data could be considered relevant to English popula-
tions, however, given the diversity in oral HPV preva-
lence rates reported globally this cannot be generalised 
to the rest of the world.
A limitation of this study, and indeed of the many 
studies measuring HPV prevalence globally, is the diver-
sity of HPV detection methods used and the HR-HPV 
subtypes included in detection. The assay chosen for 
this study was the Roche linear array HPV genotype assay 
that detects all 13 class 1 carcinogen HPV subtypes. The 
Roche linear array system was the most commonly used 
assay in the studies analysed in the recent meta-anal-
ysis (8/29 studies), even so the HPV subtypes detected 
in each of these studies varied greatly.4 Many studies 
have limited their analysis to HPV16 and HPV18 infec-
tion given their dominance in HPV infected OPC (and 
cervical neoplasia) cases, however, the data presented 
here showed that HPV16 and 18 were limited to just five 
Figure 1 Measurement of whole blood folate (left) and oral mucosal buccal epithelial cell folate (right) in samples from 
participants positive for oral HR-HPV infection (cases), participants negative for oral HR-HPV infection and participants negative 
for oral HR-HPV infection (controls) matched to HR-HPV positive participants by gender, age and smoking status. No signiicant 
differences were observed. Mean±SD. HR-HPV, high-risk human papillomavirus.
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participants, whereas the other HR-HPV subtypes were 
detected in 10 participants.
The current HPV vaccine administered to girls through 
the UK NHS is protective against four HPV strains (16, 
18, 6 and 11). The data presented here highlight the 
need for future studies which investigate the relative 
prevalence and risk of OPC development as a result of 
other HR-HPV strains and the implications this may have 
for the future development and implementation of male 
vaccinations.
Previous studies have shown a strong association 
between oral sexual experience, number of oral sexual 
partners and oral HR-HPV infection.4 16 The results from 
this study confirmed this association as it showed a signifi-
cantly increased risk of oral HR-HPV infection in those 
reporting 6–10 oral sexual partners compared with those 
with fewer than six oral sexual partners; those reporting 
more than 11 oral sexual partners showed a non-signifi-
cant increase in risk; possibly due to the smaller sample 
size. This study also showed that total number of sexual 
partners was greater for people with oral HR-HPV infec-
tion, again in line with previous studies.4 16
Smoking is reported to be associated with an increased 
risk of HR-HPV infection, with a strong association in 
females.4 Furthermore, smoking may increase the like-
lihood of an oral HR-HPV infection persisting.17 Fakhry 
et al previously showed a strong dose–response associa-
tion between tobacco exposure and oral infection with 
HPV16,18 however, in our study current smokers were 
not shown to be at significantly greater risk of HR-HPV 
infection. This may reflect in part the lower prevalence 
of smoking in this UK population (only 16% described 
themselves as current smokers) compared with the US 
population described in the Fakhry study (80% reported 
using tobacco in the previous 5 days).18 This study did 
however demonstrate that former smokers were more 
likely to have oral HR-HPV infection compared with 
those who had never smoked.
Alcohol use was not associated with incidence of oral 
HR-HPV infection in our study and this is in line with 
other findings.4 The relationship between alcohol and 
HR-HPV infection appears complex with one study 
showing a weak association with oral HR-HPV infec-
tion and heavy drinking (before accounting for sexual 
behaviour)8 and another demonstrating that those who 
had ever consumed alcohol were at a lower risk of oral 
HPV infection than never drinkers.19
Poor folate status has been linked with cancer at various 
sites including oral cavity and pharyngeal cancers,20 and 
epidemiological data are supported by plausible mecha-
nisms. Importantly, there are also some data to suggest 
that poor folate status may increase the likelihood of 
acquiring and retaining an HPV infection.9 Furthermore, 
it has been shown that low folate conditions increased 
HPV integration into the keratinocyte host genome and 
reduced viral capsid production in human keratinocytes 
in vitro.21 In this study, we found no association between 
whole blood folate concentration, oral mucosal buccal 
epithelial cell folate concentration and oral HR-HPV 
infection. This may indicate that there is no causal asso-
ciation between folate status and oral HR-HPV infection, 
but the small number of participants testing positive for 
oral HR-HPV infection in our sample will have reduced 
the likelihood of detecting such an association.
There are limitations to the study, not least the difficulty 
of drawing conclusions about risk factors for oral HR-HPV 
infection when the prevalence was low and as a result CIs 
are broad. In addition to this, questionnaires were not 
validated and relied on self-reported sexual, smoking and 
alcohol behaviours, which may not be accurate.
To our knowledge, this is the first study to examine the 
prevalence of oral HR-HPV infection in adult men and 
women in England. The prevalence is low and the data 
suggest that oral infection with HR types is associated with 
tobacco use and sexual behaviour.
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